-
Are natural remedies effective in helping reduce the hepatitis B viral load?
12 Feb 2024 11:08 GMT
… by the Food and Drug Administration (FDA). Consequently, they do … appointments.
Some herbal remedies proponents suggest can support … 2a (Pegasys). However, this is not an oral medication. Instead, … use these natural treatments with a doctor. Importantly, a …
-
Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients
20 Jun 2023 11:47 GMT
… such as sex, age, drug, HBsAg, HBeAg positive, HBeAg … used to assess internal trial consistency or to make … trials. Thirdly, many patients in our study had received NA treatment … receiving pegylated interferon-Alpha 2a (Pegasys). Medicine. 2016;95(14):e3026. …
-
Tonix Pharmaceuticals Announces Acquisition of Preclinical Infectious Disease Portfolio from Healion Bio, Inc.
02 Feb 2023 12:00 GMT
… and Drug Administration (FDA) include alpha interferon like Pegasys® (peginterferon … United States Army Medical Research Institute of … as a potential treatment for major depressive … Morris (corporate)
Tonix Pharmaceuticals
investor.relations@tonixpharma.com …
-
Will Medicaid pay for hepatitis C treatment?
25 Jul 2022 16:10 GMT
… . Older drugs include:
ribavirin
peginterferon alfa-2a (Pegasys)
peginterferon … may help with medical expenses.
Pharmaceutical programs: Some pharmaceutical companies offer … drugs can cure the condition. However, these treatments are expensive, and Medicaid …
-
Gannex Announces First Patient Dosed in Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis'
10 Apr 2022 10:51 GMT
… 2021 by China National Medical Products Administration (NMPA). … #39;Recommendations for diagnosis and treatment of primary biliary cholangitis in … R&D driven biotech listed on the Hong … antibody – ASC22 and Pegasys® as cornerstone drugs. (2) COVID-19 …
-
Ascletis Announces the Latest Results of the Preclinical Studies of Two Novel Anti-Cancer Drug Candidates, ASC61 and ASC60, to be presented at AACR Annual Meeting 2022'
27 Mar 2022 13:41 GMT
… combination with Bevacizumab for the treatment of recurrent glioblastoma (rGBM), … R&D driven biotech listed on the Hong … therapeutic areas with unmet medical needs from a global … L1 antibody – ASC22 and Pegasys® as cornerstone drugs. (2) COVID-19 …
-
Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors'
06 Feb 2022 12:07 GMT
… combination with Bevacizumab for the treatment of recurrent glioblastoma (rGBM), … R&D driven biotech listed on the Hong … therapeutic areas with unmet medical needs from a global … L1 antibody – ASC22 and Pegasys® as cornerstone drugs. (2) COVID-19 …
-
Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, An In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication'
11 Jan 2022 01:27 GMT
… normal range during 14-day treatment of the once-daily … Infectious Diseases, Nanfang Hospital, Southern Medical University.
Dr. Jinzi J. … innovative R&D driven biotech listed on the Hong … L1 antibody – ASC22 and Pegasys® as cornerstone drugs. (2) COVID-19 …
-
Ascletis Announces U.S. IND Filing for In-House Developed Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors'
10 Jan 2022 01:38 GMT
… combination with Bevacizumab for the treatment of recurrent glioblastoma (rGBM), … R&D driven biotech listed on the Hong … therapeutic areas with unmet medical needs from a global … L1 antibody – ASC22 and Pegasys® as cornerstone drugs. (2) COVID-19 …
-
Gannex Announces China NMPA Approved Phase II and III Protocols of ASC42, an FXR Agonist, for Treatment of Primary Biliary Cholangitis
15 Nov 2021 03:20 GMT
… is a significant unmet medical need for PBC treatment, and from the … the principal investigator of clinical trials of ASC42 for PBC … innovative R&D driven biotech listed on the Hong Kong … -L1 antibody – ASC22 and Pegasys® as cornerstone drugs. (2) HIV/ …